All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, Delphine Hennicken, Norman Gitlin et al.|Hepatology|2015Cited by 689
646. Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled TrialSarah M. McLeod, Alison Luckey, Khurram Rana et al.|Open Forum Infectious Diseases|2026Cited by 1